{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:32:42Z","timestamp":1786984362434,"version":"build-2736575974"},"posted":{"date-parts":[[2026,4,23]]},"group-title":"In Review","reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,21]]},"abstract":"<title>Abstract<\/title>\n                <p>Purpose\n To develop and verify a physiologically based pharmacokinetic (PBPK) modeling strategy for mithramycin (MTM) and its analog, MTMSA-Trp, with the aim of projecting first-in-human plasma pharmacokinetics and supporting the translational development of MTMSA-Trp for Ewing sarcoma treatment.\nMethods\n PBPK models were created in GastroPlus\u00ae using a middle-out approach, incorporating preclinical pharmacokinetic data from mice, rats, and cynomolgus monkeys. Human clearance was estimated through three methods: an additional clearance approach, allometric scaling, and single-species scaling from monkeys. The model was evaluated using clinical MTM plasma PK data and then employed to project human MTMSA-Trp plasma PK, with tissue predictions considered exploratory.\nResults\n  The additional clearance approach provided the most accurate prediction of human MTM plasma PK. Across all clearance prediction methods, MTMSA-Trp was predicted to achieve 8- to 15-fold higher human plasma exposure than MTM at the same dose. Model-derived liver exposures were 2- to 4-fold higher, with a lower predicted liver partition for MTMSA-Trp; however, these tissue predictions remained sensitive to distribution assumptions. Parameter sensitivity analysis identified the blood-to-plasma ratio as the most influential parameter among those examined.\nConclusion\n PBPK modeling supports the projection that MTMSA-Trp will achieve substantially higher plasma exposure than MTM in humans. This empirically developed workflow may inform translational efforts for the first-in-human development of MTMSA-Trp.<\/p>","DOI":"10.21203\/rs.3.rs-9488905\/v1","type":"posted-content","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:26:47Z","timestamp":1776929207000},"source":"Crossref","is-referenced-by-count":0,"title":["Physiologically Based Pharmacokinetic Modeling to Predict Human Pharmacokinetics of a Novel Mithramycin Analog for Ewing Sarcoma"],"prefix":"10.21203","author":[{"given":"Kumar Kulldeep","family":"Niloy","sequence":"first","affiliation":[{"name":"St. Jude Children's Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Horn","sequence":"additional","affiliation":[{"name":"St. Jude Children's Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazmul Hasan","family":"Bhuiyan","sequence":"additional","affiliation":[{"name":"University of Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhas S.","family":"Bhosale","sequence":"additional","affiliation":[{"name":"University of Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled A.","family":"Shaaban","sequence":"additional","affiliation":[{"name":"University of Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Prisinzano","sequence":"additional","affiliation":[{"name":"University of Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon S.","family":"Thorson","sequence":"additional","affiliation":[{"name":"University of Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Rohr","sequence":"additional","affiliation":[{"name":"University of Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markos","family":"Leggas","sequence":"additional","affiliation":[{"name":"St. Jude Children's Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"7Supplement","key":"ref1","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1158\/1538-7445.Am2026-3504","article-title":"Abstract 3504: Mithramycin analogues trap the EWS-FLI1 transcriptional complex, evict ETV6, and disable oncogenic condensate function in Ewing sarcoma","volume":"86","author":"Acharya S","year":"2026","unstructured":"Acharya S, Yetirajam R, Kazuto Y, Bhosale S, Rohr J, Leggas M (2026) Abstract 3504: Mithramycin analogues trap the EWS-FLI1 transcriptional complex, evict ETV6, and disable oncogenic condensate function in Ewing sarcoma. Cancer Res 86(7Supplement):3504\u20133504. 10.1158\/1538-7445.Am2026-3504","journal-title":"Cancer Res"},{"issue":"8Supplement1","key":"ref2","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1158\/1538-7445.Am2025-4360","article-title":"Abstract 4360: Development of a novel mithramycin analogue with improved pharmacokinetics and therapeutic window for targeted inhibition of EWS-FLI1 in Ewing sarcoma","volume":"85","author":"Yetirajam R","year":"2025","unstructured":"Yetirajam R, Acharya S, Niloy KK, Kazuto Y, Horn J, Prisinzano T, Thorson JS, Tsodikov O, Rohr J, Leggas M (2025) Abstract 4360: Development of a novel mithramycin analogue with improved pharmacokinetics and therapeutic window for targeted inhibition of EWS-FLI1 in Ewing sarcoma. Cancer Res 85(8Supplement1):4360\u20134360. 10.1158\/1538-7445.Am2025-4360","journal-title":"Cancer Res"},{"issue":"6","key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17060765","article-title":"Preclinical Pharmacokinetic Evaluation of Mithramycin and Mithramycin SA Tryptophan-Conjugated Analog","volume":"17","author":"Niloy KK","year":"2025","unstructured":"Niloy KK, Horn J, Bhuiyan NH, Shaaban KA, Bhosale SS, Prisinzano TE, Thorson JS, Rohr J, Leggas M (2025) Preclinical Pharmacokinetic Evaluation of Mithramycin and Mithramycin SA Tryptophan-Conjugated Analog. Pharmaceutics 17(6). 10.3390\/pharmaceutics17060765","journal-title":"Pharmaceutics"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-9035594\/v1","article-title":"Nonlinear Mixed-Effects Modeling to Characterize the Pharmacokinetics of a Novel Mithramycin Analogue for Ewing Sarcoma in Mice. PREPRINT (Version 1) available at Research Square","author":"Niloy KK","year":"2026","unstructured":"Niloy KK, Horn J, Bhuiyan NH, Shaaban KA, Bhosale SS, Prisinzano TE, Thorson JS, Rohr J, Leggas M (2026) Nonlinear Mixed-Effects Modeling to Characterize the Pharmacokinetics of a Novel Mithramycin Analogue for Ewing Sarcoma in Mice. PREPRINT (Version 1) available at Research Square. 10.21203\/rs.3.rs-9035594\/v1"},{"key":"ref5","article-title":"Bridging Tumor Growth Dynamics and Survival in Preclinical Oncology Drug Development: A Translational Tumor Growth Inhibition and Time-to-Event (TGI-TTE) Modeling Framework","author":"Niloy K","year":"2026","unstructured":"Niloy K, Leggas M (2026) Bridging Tumor Growth Dynamics and Survival in Preclinical Oncology Drug Development: A Translational Tumor Growth Inhibition and Time-to-Event (TGI-TTE) Modeling Framework. Clin Pharmacol Ther 119"},{"issue":"6","key":"ref6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40262-019-00741-9","article-title":"Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies","volume":"58","author":"Miller NA","year":"2019","unstructured":"Miller NA, Reddy MB, Heikkinen AT, Lukacova V, Parrott N (2019) Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies. Clin Pharmacokinet 58(6):727\u2013746. 10.1007\/s40262-019-00741-9","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/bdd.2359","article-title":"Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds","volume":"44","author":"Mao J","year":"2023","unstructured":"Mao J, Ma F, Yu J, Bruyn T, Ning M, Bowman C, Chen Y (2023) Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds. Biopharm Drug Dispos 44(4):315\u2013334. 10.1002\/bdd.2359","journal-title":"Biopharm Drug Dispos"},{"issue":"7","key":"ref8","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s11095-024-03725-y","article-title":"A Combination of Machine Learning and PBPK Modeling Approach for Pharmacokinetics Prediction of Small Molecules in Humans","volume":"41","author":"Li Y","year":"2024","unstructured":"Li Y, Wang Z, Li Y, Du J, Gao X, Li Y, Lai L (2024) A Combination of Machine Learning and PBPK Modeling Approach for Pharmacokinetics Prediction of Small Molecules in Humans. Pharm Res 41(7):1369\u20131379. 10.1007\/s11095-024-03725-y","journal-title":"Pharm Res"},{"issue":"6","key":"ref9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1208\/s12248-025-01138-2","article-title":"Clinical Ocular Exposure Extrapolation for an Ophthalmic Ointment Using PBPK Modeling and Simulation","volume":"27","author":"Merdy M","year":"2025","unstructured":"Le Merdy M, Tan ML, Lukacova V (2025) Clinical Ocular Exposure Extrapolation for an Ophthalmic Ointment Using PBPK Modeling and Simulation. AAPS J 27(6):150. 10.1208\/s12248-025-01138-2","journal-title":"AAPS J"},{"issue":"1","key":"ref10","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1002\/jcph.2117","article-title":"Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies","volume":"62","author":"Balhara A","year":"2022","unstructured":"Balhara A, Kumar AR, Unadkat JD (2022) Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies. J Clin Pharmacol 62(1):S94\u2013s114. 10.1002\/jcph.2117","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"ref11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00280-017-3382-x","article-title":"A phase I\/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript","volume":"80","author":"Grohar PJ","year":"2017","unstructured":"Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ, Widemann BC (2017) A phase I\/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. Cancer Chemother Pharmacol 80(3):645\u2013652. 10.1007\/s00280-017-3382-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"ref12","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1002\/jps.21759","article-title":"Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods","volume":"98","author":"Poulin P","year":"2009","unstructured":"Poulin P, Theil FP (2009) Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci 98(12):4941\u20134961. 10.1002\/jps.21759","journal-title":"J Pharm Sci"},{"issue":"2","key":"ref13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40262-024-01444-6","article-title":"All You Need to Know About Allometric Scaling: An Integrative Review on the Theoretical Basis, Empirical Evidence, and Application in Human Pharmacology","volume":"64","author":"Valkengoed DW","year":"2025","unstructured":"van Valkengoed DW, Krekels EHJ, Knibbe CAJ (2025) All You Need to Know About Allometric Scaling: An Integrative Review on the Theoretical Basis, Empirical Evidence, and Application in Human Pharmacology. Clin Pharmacokinet 64(2):173\u2013192. 10.1007\/s40262-024-01444-6","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"ref14","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1476-5381.2009.00267.x","article-title":"To scale or not to scale: the principles of dose extrapolation","volume":"157","author":"Sharma V","year":"2009","unstructured":"Sharma V, McNeill JH (2009) To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157(6):907\u2013921. 10.1111\/j.1476-5381.2009.00267.x","journal-title":"Br J Pharmacol"},{"issue":"6","key":"ref15","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1124\/dmd.118.085605","article-title":"Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy","volume":"47","author":"Pierrillas PB","year":"2019","unstructured":"Pierrillas PB, Henin E, Ball K, Ogier J, Amiel M, Kraus-Berthier L, Chenel M, Bouzom F, Tod M (2019) Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy. Drug Metab Dispos 47(6):648\u2013656. 10.1124\/dmd.118.085605","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"ref16","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1124\/dmd.122.000885","article-title":"Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib","volume":"50","author":"Lin L","year":"2022","unstructured":"Lin L, Wright MR, Hop C, Wong H (2022) Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib. Drug Metab Dispos 50(9):1170\u20131181. 10.1124\/dmd.122.000885","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"ref17","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s11030-021-10186-7","article-title":"Predicting blood-to-plasma concentration ratios of drugs from chemical structures and volumes of distribution in humans","volume":"25","author":"Mamada H","year":"2021","unstructured":"Mamada H, Iwamoto K, Nomura Y, Uesawa Y (2021) Predicting blood-to-plasma concentration ratios of drugs from chemical structures and volumes of distribution in humans. Mol Divers 25(3):1261\u20131270. 10.1007\/s11030-021-10186-7","journal-title":"Mol Divers"},{"issue":"2","key":"ref18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1124\/dmd.120.000202","article-title":"Predicting Volume of Distribution in Humans: Performance of In Silico Methods for a Large Set of Structurally Diverse Clinical Compounds","volume":"49","author":"Murad N","year":"2021","unstructured":"Murad N, Pasikanti KK, Madej BD, Minnich A, McComas JM, Crouch S, Polli JW, Weber AD (2021) Predicting Volume of Distribution in Humans: Performance of In Silico Methods for a Large Set of Structurally Diverse Clinical Compounds. Drug Metab Dispos 49(2):169\u2013178. 10.1124\/dmd.120.000202","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"ref19","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1007\/s11095-015-1749-4","article-title":"Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)","volume":"32","author":"Varma MV","year":"2015","unstructured":"Varma MV, Steyn SJ, Allerton C, El-Kattan AF (2015) Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS). Pharm Res 32(12):3785\u20133802. 10.1007\/s11095-015-1749-4","journal-title":"Pharm Res"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9488905\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9488905\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:09:35Z","timestamp":1786982975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9488905\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":19,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9488905\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1007\/s00280-026-04935-4","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,4,23]]},"subtype":"preprint"}}